Glucose-6-phosphate dehydrogenase deficiency primary prevention

Glucose-6-phosphate dehydrogenase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Glucose-6-phosphate dehydrogenase deficiency primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Glucose-6-phosphate dehydrogenase deficiency primary prevention
CDC on Glucose-6-phosphate dehydrogenase deficiency primary prevention
Glucose-6-phosphate dehydrogenase deficiency primary prevention in the news
Blogs on Glucose-6-phosphate dehydrogenase deficiency primary prevention
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]

Overview

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include:

• [Measure1]
• [Measure2]
• [Measure3]

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:

• [Strategy 1]
• [Strategy 2]
• [Strategy 3]

References

Glucose-6-phosphate dehydrogenase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Glucose-6-phosphate dehydrogenase deficiency primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Glucose-6-phosphate dehydrogenase deficiency primary prevention
CDC on Glucose-6-phosphate dehydrogenase deficiency primary prevention
Glucose-6-phosphate dehydrogenase deficiency primary prevention in the news
Blogs on Glucose-6-phosphate dehydrogenase deficiency primary prevention
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [4]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive hereditary disease featuring abnormally low levels of the G6PD enzyme, which plays an important role in red blood cell function. Individuals with the disease may exhibit non-immune hemolytic anemia in response to a number of causes. It is closely linked to favism, a disorder characterized by a hemolytic reaction to consumption of broad beans, with a name derived from the Italian name of the broad bean (fava). Sometimes the name, favism, is alternatively used to refer to the enzyme deficiency as a whole.

Primary Prevention

• The most important measure is prevention - avoidance of the drugs and foods that cause hemolysis.
• Vaccination against some common pathogens (e.g. hepatitis A) may prevent infection-induced attacks.

References

Template:WikiDoc Sources Need content